151 related articles for article (PubMed ID: 38581379)
1. Gammopathic dermopathy: characterization of cutaneous MGUS.
Gordon ER; Chen C; Trager MH; Adeuyan O; Lapolla BA; Fahmy LM; Schreidah CM; Wetter DA; Geskin LJ
Leuk Lymphoma; 2024 Apr; ():1-8. PubMed ID: 38581379
[TBL] [Abstract][Full Text] [Related]
2. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
4. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
5. The dilemma of treating pyoderma gangrenosum associated with monoclonal gammopathy of undetermined significance.
Machan A; Azendour H; Frikh R; Hjira N; Boui M
Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621712
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of multiple myeloma drug use in cutaneous toxicity of monoclonal gammopathy of undetermined significance.
Gordon ER; Chen C; Adeuyan O; Lapolla BA; Trager MH; Fahmy LM; Schreidah CM; Wetter DA; Geskin LJ
J Am Acad Dermatol; 2024 Jul; 91(1):129-130. PubMed ID: 38479611
[No Abstract] [Full Text] [Related]
7. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
[TBL] [Abstract][Full Text] [Related]
8. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Gammopathy of Undetermined Significance.
Gonsalves WI; Rajkumar SV
Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
[TBL] [Abstract][Full Text] [Related]
10. Neurologic aspects of plasma cell disorders.
Sobol U; Stiff P
Handb Clin Neurol; 2014; 120():1083-99. PubMed ID: 24365373
[TBL] [Abstract][Full Text] [Related]
11. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
[TBL] [Abstract][Full Text] [Related]
13. Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.
Paludo J; Ansell SM
F1000Res; 2017; 6():2142. PubMed ID: 29399323
[TBL] [Abstract][Full Text] [Related]
14. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
16. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Go RS; Gundrum JD; Neuner JM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
[TBL] [Abstract][Full Text] [Related]
17. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese.
Lee LN; Jan IS; Tien HF; Lin JS; Lo SC; Cheng WC
J Formos Med Assoc; 2002 Feb; 101(2):91-7. PubMed ID: 12099210
[TBL] [Abstract][Full Text] [Related]
18. Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy.
Al-Zuhairy A; Schrøder HD; Plesner T; Abildgaard N; Sindrup SH
J Neurol Sci; 2015 Feb; 349(1-2):60-4. PubMed ID: 25582978
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
